-The Times of India   The unveiling of the draft National Land Acquisition and Rehabilitation and Resettlement Bill is better late than never. All over India, industrialisation and infrastructure are hobbled by land-related strife. Whether it's Singur in Bengal or anti-Posco protests in Orissa, such stirs are impeding development and spooking investors. Bringing in a set of predictable rules - any rules - is welcome in such a context. The Bill...

The Congress-led United Progressive Alliance government’s proposed land acquisition law, a politically sensitive and critical piece of legislation that could potentially remove a big roadblock to industrial investment, aims to address rehabilitation and resettlement (R&R), providing safeguards for both land owners and livelihood losers, while clearly defining the “public purpose” for which land can be acquired by the government. “This draft Bill seeks to balance the need for facilitating land acquisition...

States are expected to take responsibility for this, but the Bill ignores the nutritional crisis altogether K V Thomas Minister for Food The inclusion of iron supplements, protein, dairy supplements and vegetables can be done gradually - this Bill is just the beginning The food security Bill will certainly ensure nutrition but it is the states that have to take steps for that. The draft Bill approved recently by the Group of Ministers is...

If Rajiv Gandhi were alive, he would have been delighted to see his view on leakages confirmed by a research study on the public distribution system [How Can Food Subsidies Work Better? Answers from India and the Philippines by Shikha Jha and Bharat Ramaswami (http://www.adb.org/documents/working-papers/2010/economics-wp221.pdf)]. The ADB study showed that the deserving poor in India received only 10 per cent of the benefits from the system. Nearly twice accrues to...

Last month, the Archives of Internal Medicine published a scathing reassessment of a 12-year-old research study of Neurontin, a seizure drug made byPfizer. The study, which had included more than 2,700 subjects and was carried out by Parke-Davis (now part of Pfizer), was notable for how poorly it was conducted. The investigators were inexperienced and untrained, and the design of the study was so flawed it generated few if any...